Aggressiveness pattern and second primary tumor risk associated with basaloid squamous cell carcinoma of the larynx

// Filippo Ricciardiello 1 , Michele Caraglia 3 , Brigida Iorio 2 , Teresa Abate 1 , Mariarosaria Boccellino 3 , Giuseppe Colella 4 , Flavia Oliva 1 , Pierpaolo Ferrise 1 , Silvia Zappavigna 3 , Mario Faenza 4 , Giuseppe A. Ferraro 4 , Giulio Sequino 1 , Giovanni Francesco Nicoletti 4 and Massimo Mesolella 2 1 Division of Otolaryngology, “A. Cardarelli” Hospital, Naples, Italy 2 Department of Neurological, Reproductive and Odontostomatological Sciences, University “Federico II” of Naples, Naples, Italy 3 Department of Biochemistry, Biophysics and General Pathology, University of Campania “L. Vanvitelli”, Naples, Italy 4 Department of Medical, Surgical and Dental Specialties, University of Campania “L. Vanvitelli”, Naples, Italy Correspondence to: Michele Caraglia, email: michele.caraglia@unina2.it , michele.caraglia@fastwebnet.it Keywords: laryngea lbasaloid squamocellular carcinoma (BSCC); prognosis of laryngeal basaloid squamous cell carcinoma; mortality of laryngeal BSCC; loco-regional recurrence in laryngeal BSCC Received: July 26, 2017     Accepted: August 23, 2017     Published: September 28, 2017 ABSTRACT Basaloid squamous cell carcinoma (BSCC) is a rare, aggressive and distinct variant of squamous cell carcinoma (SCC) of the upper respiratory and digestive tract. We have evaluated disease specific survival (DSS) and overall survival (OS) through Kaplan-Meier method and mortality risk through univariate statistical analysis of Cox in 42 cases of BSCC and other 42 of laryngeal SCC (LSCC) matched for both age and sex. We demonstrated that laryngeal BSCC is a more aggressive tumor than LSCC as is associated to higher nodal recurrence of pathology ( 5 vs 2 patients, overall risk, OR 2.7), a reduced survival (median survival 34 vs 40 months, OR 3.2 for mortality); in addition, basaloid patients have a higher risk to be affected by second primary tumors (13 vs 3 patients, OR 5.8) and a higher probability to die for this second tumor (Hazard Risk, HR 4.4). The analysis of survival shows an increased mortality risk concurrent with the parameters assessed by univariate analyses that assume a predictive and statistical significance in second tumor and grading in basaloid LSSC.